Lentivirally Redirected CD123 Autologous T Cells in AML

Phase 1 Terminated 22 enrolled University of Pennsylvania

Non-randomizedSequentialOpen-labelTreatment

Summary

Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in Acute Myeloid Leukemia (AML) subjects.

Timeline

Start: 2018-12-06
Primary completion: 2026-03-05
Completion: 2026-03-05

Publications

Bhagwat AS, Torres L, Shestova O, Shestov M, Mellors PW, Fisher HR, Farooki SN, Frost BF, Loken MR, Gaymon AL, Frazee D, Rogal W, Frey N, Hexner EO, Luger SM, Loren AW, Martin ME, McCurdy SR, Perl AE, Stadtmauer EA, Brogdon JL, Fraietta JA, Hwang WT, Siegel DL, Plesa G, Aplenc R, Porter DL, June CH, Gill SI. Cytokine-mediated CAR T therapy resistance in AML. Nat Med. 2024 Dec;30(12):3697-3708. doi: 10.1038/s41591-024-03271-5. Epub 2024 Sep 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CART123 cells	Cell therapy	1e+06 cells/kg	Intravenous
Subject	CART123 cells	Cell therapy	2e+06 cells/kg	Intravenous
Subject	CART123 cells	Cell therapy	5e+06 cells/kg	Intravenous
Background	Cyclophosphamide	Other / unclassified	—	—
Background	Fludarabine	Small molecule	—	—

Lentivirally Redirected CD123 Autologous T Cells in AML

Summary

Timeline

Publications

Drugs

Indications